Navigation Links
Regeneron Increases Size of Public Offering of Common Stock
Date:10/8/2010

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi is serving as sole book-running manager for the offering. The offering is expected to close on October 13, 2010, subject to customary closing conditions.  In addition, Regeneron has granted Citi a 30-day option to purchase up to an additional 825,000 shares of Common Stock to cover over-allotments, if any. The shares are being offered by Regeneron under the Company's shelf registration statement.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  Copies of the prospectus supplement and accompanying prospectus related to this offering may be obtained by sending a request to the offices of Citi at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, telephone number (800) 831-9146.  Alternatively, these documents are available by visiting EDGAR on the SEC website at www.sec.gov.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
2. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
3. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
4. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
5. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
6. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
7. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
8. Regeneron Reports Third Quarter 2009 Financial and Operating Results
9. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
10. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... According to Marcia Crosse (Director, Health Care at GAO ... health has been compromised. In her comments on why oversight ... says : "The Food and Drug ... all Americans. FDA,s role is far-reaching: from over-the-counter pain relievers ...
... 19, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development ... the first milestone in its strategic partnership with ... Chinese pharmaceutical company, to develop novel therapeutic monoclonal ...
Cached Medicine Technology:Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 2Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 3Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 4ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 2ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 3ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 4
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... STANFORD, Calif. Consider the marvel of the embryo. It ... and function as they multiply to become the cells of ... of the body. , Now, in a feat of reverse ... complex genetic coding that allows embryonic cells to proliferate and ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... the United States have nearly doubled since 1988, suggests new ... with obesity apparently to blame for the surge. The researchers ... hit all groups equally, with alarming increases in diabetes in ... reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... the RECIST Working Group published in the European Journal ... refined categorization of tumor response or various aspects of progression ... They found that modeling target lesion tumor growth did ... that of the other components of progression. The RECIST Working ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... certain heart patients will fare about the same whether ... that uses drug-coated stents to prop open clogged arteries. ... procedures, which also require much less recovery time. However, ...
... Cincinnati (UC) and Cincinnati Children,s Hospital Medical Center ... primarily to prevent rejection in organ transplant patients, ... The Multicenter International LAM Efficacy of Sirolimus ... designed to develop a therapy for this life-threatening ...
... MD, MPH, Medical Director and Principal Investigator of IMPACT ... Children,s National Medical Center, served as the Site Principal Investigator ... outcomes, specifically for inner-city children and teens. Findings from a ... were published and released in the March 17 issue of ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... drug cytarabine work as well as the high doses that ... fewer side effects, a new Dutch study finds. Cytarabine ... along with other chemotherapy drugs and stem cell transplantation. Cytarabine ...
... It is no surprise to scientists that the largest social ... their face is fundamental to our social interactions, one of ... how our brain processes facial identity. In a ... scientists used an original approach a method that "shakes" ...
Cached Medicine News:Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 2Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 3Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Innovative technique gives vision researchers insight into how people recognize faces 2
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: